Duracyte Inc.

Duracyte Inc. operates as a federal grant subcontractor, delivering research and development services under the National Institutes of Health through academic prime recipients, with all three recent awards subawarded by William Marsh Rice University under the THOR (Targeted Hybrid Oncotherapeutic Regulation) program.

Duracyte is a for-profit corporate entity with no prime federal contract or grant awards and no seats on federal contract vehicles. The vendor's federal footprint consists entirely of subawarded grant work — three awards between December 2024 and March 2026, totaling $7.1 million obligated dollars. All work flows through the Department of Health and Human Services National Institutes of Health as the grantor agency, with William Marsh Rice University as the prime grant recipient on each award. The three sub-awards represent consistent quarterly or semi-annual funding increments to the same underlying THOR initiative, suggesting sustained engagement on a multi-year program rather than discrete project awards. The vendor operates exclusively in the grant-recipient space without commercial contract vehicle presence, meaning it does not compete for federal task orders through GWACs, BPAs, IDIQs, or agency schedules and carries no set-aside designations.

Activity is minimal and recent — one award per calendar year in 2024, 2025, and 2026 — with no recompete cliff visible in the source data. The vendor's federal customer base is concentrated in a single agency (Department of Health and Human Services National Institutes of Health, 100% of awards). Duracyte's federal identity is that of a specialized oncology research subcontractor embedded in an academic prime organization, with no visibility into federal procurement channels, vehicle positioning, or broader customer diversification.